Annovis Bio stock reports 862 Phase 3 enrollments

Annovis Bio stock stood at USD 1.27 on the NYSE on September 23, 2026, up USD 0.01 or 0.79 percent from USD 1.26. The company then announced a regulatory partnership that puts its next clinical milestone on a defined calendar.

862 patients enter Phase 3

As Manila Times reported on September 23, 2026, Annovis Bio partnered with Weave Bio to draft, review and manage documents for a planned New Drug Application for buntanetap.

The pivotal Phase 3 Alzheimer trial enrolled 862 biomarker-confirmed patients, exceeding its original 760-patient target by 102 participants. The company aims for database lock in December 2026 and a top-line symptomatic data announcement in March 2027, creating two dated checkpoints for the program.

Cash falls as research spending rises

Longevity Technology reported that Annovis Bio's second-quarter 2026 net loss was USD 14.8 million, compared with USD 6.2 million a year earlier. Research spending rose to USD 12 million from USD 5.2 million over the same comparison.

Cash stood at USD 18.7 million as of June 30, 2026, down from USD 19.5 million at the start of the year. The contrast is central to the stock story: clinical progress has expanded, but the cost base has also widened as the Phase 3 program advances.

Stock stays below yearly high

At USD 1.27 on September 23, 2026, Annovis Bio stock was 76.9 percent below its 52-week high of USD 5.50 and USD 0.23 above its 52-week low of USD 1.04. The price therefore reflects a late-stage biotech valuation still tied closely to trial execution and future financing needs.

Stock Titan identifies Annovis Bio as a healthcare biotechnology company listed on the NYSE under ticker ANVS and reports a special meeting scheduled for October 14, 2026. The meeting includes a proposal to increase authorized common stock from 70 million to 140 million shares, a capital-structure issue that adds another measurable consideration for shareholders.

Clinical dates set the timetable

Annovis Bio stock carries a single near-term narrative: the 862-patient trial has moved from enrollment to data preparation, while December 2026 and March 2027 mark the next stated milestones. The September 23 price of USD 1.27 and the Q2 cash balance of USD 18.7 million frame the opportunity and funding pressure around that timetable.